Alzheimer’s and ADHD Reviewed

The September/October issue of NeuroPerspective features our annual, epic, and comprehensive review of the Alzheimer’s space, including a review of the current thinking around pathophysiology and therapeutic targets:An updated assessment on the roles of amyloid, tau, neuroinflammation, and other targets is included. The subtitle for the review is ¬†‘Reset, Reboot,Recalibrate’, because the traditional modus operandi for the Industry in its approach to AD has produced little beyond a series of dispiriting failures and mediocre demi-signals. ¬†

Among the 150+ programs are assessed are those from: AbbVie, AB Science, AC Immune, AgeneBio, Allergan, Alkahest, Anavex, Asceneuron, AstraZeneca, Axon-Neuroscience, Axovant, Biogen, Cognition Therapeutics, Cortexyme, Denali, Eisai, E-Scape, Genentech, Intra-Cellular, JNJ, Karuna, Lilly, Lundbeck, Merck, Novartis, Oryzon, Pfizer, Prana, Probiodrug, Proclara, ProMIS, Roce, Takeda, TauRx, Tetra Drug Discovery, United Neuroscience, and Voyager. Alkahest is the focus of the Company Review, sidebars include coverage of the current state of the AD Biomarker art and a consideration of the POC timelines for major AD programs.

The Sept/Oct issue also includes a full review of ADHD, including the search for nonstimulant options that might approach the efficacy of the psychostimulants. Programs from Aevi, Alcobra, NLS Pharma, Otsuka/Neurovance, Sunovion, and Supernus are among those assessed in the review.

75 pages.